middle.news

OncoSil’s OSPREY Registry Signals New Hope for Advanced Pancreatic Cancer Survival

9:41am on Wednesday 3rd of December, 2025 AEDT • Healthcare
Read Story

OncoSil’s OSPREY Registry Signals New Hope for Advanced Pancreatic Cancer Survival

9:41am on Wednesday 3rd of December, 2025 AEDT
Key Points
  • First interim analysis of 64 patients treated with OncoSil™ plus gemcitabine chemotherapy
  • Median overall survival of 20.6 to 22.0 months in first-line patients, surpassing historical chemotherapy outcomes
  • Low incidence of mild adverse device events with no serious complications reported
  • Data submitted for presentation at ESGE Days 2026 in Milan
 Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about OSL
OPEN ARTICLE